Efficacy of antineoplastons A10 and AS2-1

Mayo Clin Proc. 1999 Jun;74(6):641-2. doi: 10.4065/74.6.641.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / adverse effects
  • Benzeneacetamides*
  • Clinical Trials as Topic
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Combinations
  • Glioma / blood
  • Glioma / drug therapy*
  • Glioma / secondary
  • Glutamine / administration & dosage
  • Glutamine / adverse effects
  • Glutamine / analogs & derivatives*
  • Glutamine / blood
  • Humans
  • National Institutes of Health (U.S.)
  • Phenylacetates / administration & dosage*
  • Phenylacetates / adverse effects
  • Phenylacetates / blood
  • Piperidones / administration & dosage*
  • Piperidones / adverse effects
  • Treatment Failure
  • United States

Substances

  • Antineoplastic Agents
  • Benzeneacetamides
  • Drug Combinations
  • Phenylacetates
  • Piperidones
  • Glutamine
  • antineoplaston AS 2-1
  • antineoplaston A10
  • phenylacetylglutamine
  • phenylacetic acid